PHARMANEXT
ActiveSummary
The computed 12-month bankruptcy probability of PHARMANEXT is 2.1% (moderate). The 2025 annual accounts show equity of €531,183 and a net result of €169,596. Equity is growing by ~32.5% per year across the filed fiscal years. Its solvency ranks better than 34% of 12411 sector peers (fiscal year 2025). The company has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
100%
According to the 2025 annual accounts of PHARMANEXT and those of the other companies, the acts in the Belgian Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Companies Code and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 3 Gazette acts processed.